The Role of Oxytocin in the Perception of Faces

R

Rodrigo Cardenas

Status and phase

Completed
Early Phase 1

Conditions

Healthy

Treatments

Other: Placebo
Drug: Syntocinon (synthetic oxytocin)

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT02443727
STUDY00001225

Details and patient eligibility

About

The main objective of this project is to study whether intranasal oxytocin (OT) affects how young adults perceive and attend to infant and adult faces. Based on existing research the investigators predict that oxytocin will facilitate the allocation of attentional resources on infant faces (compared to adult faces). The investigators also predict that oxytocin will enhance the activity of reward neural-networks associated with the perception of infant faces. The behavioral effects of OT (visual attention and face recognition) will be measured with eye-tracking while participants look at photographs of adult and infant faces. Neurological effects (the activity of emotion and reward networks) will be measured with functional Magnetic Resonance Imaging (fMRI) while participants look at infant faces on a computer screen.

Enrollment

71 patients

Sex

Male

Ages

18 to 25 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy Volunteers
  • Norma or corrected to norma vision
  • Participants are non parents
  • Able to provide written informed consent and to comply with all study procedures

Exclusion criteria

  • Dementia or severe cognitive disorders
  • Endocrine disease or malignancy
  • Nasal obstruction or upper-respiratory tract infection
  • Current or previous psychiatric disorder
  • Current or previous use of psychoactive drugs
  • Alcoholism or substance abuse
  • History of seizures
  • Neurological Disorder
  • Previous head trauma
  • Hypertension
  • Cardiovascular Disease
  • Claustrophobia
  • ferrous metal in any part of the body

Trial design

71 participants in 2 patient groups, including a placebo group

Intranasal oxytocin group
Experimental group
Description:
Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).
Treatment:
Drug: Syntocinon (synthetic oxytocin)
Placebo group
Placebo Comparator group
Description:
The placebo is identical to the oxytocin formulation with the exception of the active compound. Participants will self-administer three puffs per nostril of placebo (6 puffs total).
Treatment:
Other: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems